Functional impact of dendritic cell phenotype in a mouse model of myositis

树突状细胞表型对肌炎小鼠模型的功能影响

基本信息

项目摘要

DESCRIPTION (provided by applicant): In the idiopathic inflammatory myopathies, disease pathogenesis remains largely undefined. However, we have recently published work demonstrating that immunization of different NOD and C57BL/6 congenic strains with murine histidyl-tRNA synthetase (Jo-1) generates muscle and lung inflammation resembling features of the anti-synthetase syndrome. The experimental approach outlined in this application extends these earlier studies through functional manipulation of dendritic cell (DC) phenotype to define characteristics of the Jo-1-specific immune response contributing to disease expression. Specific Aim 1 employs different in vitro cytokine preparations and maturation stimuli to generate Jo-1-loaded DCs capable of skewing toward Th1, Th2, or Th17 immune responses targeting this antigen. Subsequent immunization of NOD and C57BL/6 congenic mice with Jo- 1-pulsed DCs cultivated under defined conditions will highlight the impact of antigen-specific T cell polarization on tissue inflammation in comparison to Jo-1/CFA immunization. Adoptive transfer of organ-infiltrating lymphocytes from DC-immunized to naive mice will firmly establish the relationship between Jo-1-specific autoimmune responses and the anti-synthetase syndrome. Parallel measurement of CFSE-labeled T cell proliferative responses and intracellular cytokine staining of antigen-challenged lymphocytes derived from spleen and organ-draining lymph nodes of DC-immunized mice will further link the observed tissue phenotype to Th17 and/or Th1-polarized, Jo-1-specific T cell responses. In contrast, use of alternative cytokine conditioning in Specific Aim 2 will generate Jo-1-loaded "tolerogenic" DCs capable of blocking disease induction and, more importantly, re-establishing tolerance in existing disease. Complementing the in vivo assessment of Jo-1-pulsed tolerogenic DC immunization in disease preventioNot applicable.melioration, in vitro transwell mixing and antibody blocking experiments will define the relative contribution of anergy, bystander suppression, and contact-mediated inhibition to antigen-specific regulatory T cell function. The mechanistic insight provided by these studies will help to define immunologic targets and therapeutic approaches applicable to future human clinical trials. PUBLIC HEALTH RELEVANCE: This project employs functional manipulation of antigen-pulsed dendritic cells to define the role of Jo-1-specific T cells in a murine model of inflammatory myopathy. This approach will clarify mechanisms of disease initiation/perpetuation and establish the feasibility of antigen- specific, dendritic cell-mediated tolerance induction. The latter objective is relevant to the treatment of multiple autoimmune diseases for which global immunosuppression is the only therapeutic option.
描述(由申请人提供):在特发性炎性肌病中,疾病发病机制在很大程度上仍不明确。然而,我们最近发表的工作表明,不同的NOD和C57 BL/6同源株与鼠组氨酰-tRNA合成酶(Jo-1)的免疫产生肌肉和肺部炎症类似的抗合成酶综合征的功能。本申请中概述的实验方法通过树突状细胞(DC)表型的功能操作来扩展这些早期研究,以定义有助于疾病表达的Jo-1特异性免疫应答的特征。特异性目的1采用不同的体外细胞因子制剂和成熟刺激物来产生能够偏向于靶向该抗原的Th 1、Th 2或Th 17免疫应答的Jo-1负载的DC。随后用在限定条件下培养的Jo- 1脉冲的DC免疫NOD和C57 BL/6同源小鼠,与Jo-1/CFA免疫相比,将突出抗原特异性T细胞极化对组织炎症的影响。器官浸润淋巴细胞从DC免疫的幼稚小鼠的连续转移将牢固地建立Jo-1特异性自身免疫反应和抗合成酶综合征之间的关系。平行测量CFSE标记的T细胞增殖反应和源自DC免疫小鼠脾脏和器官引流淋巴结的抗原激发淋巴细胞的细胞内细胞因子染色将进一步将观察到的组织表型与Th 17和/或Th 1极化的Jo-1特异性T细胞反应联系起来。相比之下,在特异性目标2中使用替代性细胞因子调节将产生能够阻断疾病诱导并且更重要地,在现有疾病中重建耐受性的Jo-1负载的“致耐受性”DC。补充体内评估Jo-1脉冲致耐受性DC免疫在疾病预防中的作用,体外transwell混合和抗体阻断实验将确定无反应性、旁观者抑制和接触介导的抑制对抗原特异性调节性T细胞功能的相对贡献。这些研究提供的机制见解将有助于确定适用于未来人体临床试验的免疫靶点和治疗方法。公共卫生相关性:该项目采用抗原脉冲树突状细胞的功能操作来定义Jo-1特异性T细胞在炎症性肌病小鼠模型中的作用。这种方法将阐明疾病引发/持续的机制,并建立抗原特异性、树突细胞介导的耐受诱导的可行性。后一个目标与多种自身免疫性疾病的治疗有关,其中全身免疫抑制是唯一的治疗选择。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DANA P ASCHERMAN其他文献

DANA P ASCHERMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DANA P ASCHERMAN', 18)}}的其他基金

Evaluating Clinical and Immunological Consequences of SARS-CoV-2 Vaccination in Rheumatic Disease
评估风湿性疾病中 SARS-CoV-2 疫苗接种的临床和免疫学后果
  • 批准号:
    10532784
  • 财政年份:
    2021
  • 资助金额:
    $ 20.45万
  • 项目类别:
Evaluating Clinical and Immunological Consequences of SARS-CoV-2 Vaccination in Rheumatic Disease
评估风湿性疾病中 SARS-CoV-2 疫苗接种的临床和免疫学后果
  • 批准号:
    10362978
  • 财政年份:
    2021
  • 资助金额:
    $ 20.45万
  • 项目类别:
Innate Immune Activation in Autoimmune Myopathy
自身免疫性肌病的先天免疫激活
  • 批准号:
    9926715
  • 财政年份:
    2017
  • 资助金额:
    $ 20.45万
  • 项目类别:
Innate Immune Activation in Autoimmune Myopathy
自身免疫性肌病的先天免疫激活
  • 批准号:
    9286500
  • 财政年份:
    2017
  • 资助金额:
    $ 20.45万
  • 项目类别:
Peripheral Blood Biomarkers of RA-associated Interstitial Lung Disease
RA 相关间质性肺病的外周血生物标志物
  • 批准号:
    8278446
  • 财政年份:
    2011
  • 资助金额:
    $ 20.45万
  • 项目类别:
Peripheral Blood Biomarkers of RA-associated Interstitial Lung Disease
RA 相关间质性肺病的外周血生物标志物
  • 批准号:
    8397571
  • 财政年份:
    2011
  • 资助金额:
    $ 20.45万
  • 项目类别:
Peripheral Blood Biomarkers of RA-associated Interstitial Lung Disease
RA 相关间质性肺病的外周血生物标志物
  • 批准号:
    8142414
  • 财政年份:
    2011
  • 资助金额:
    $ 20.45万
  • 项目类别:
Peripheral Blood Biomarkers of RA-associated Interstitial Lung Disease
RA 相关间质性肺病的外周血生物标志物
  • 批准号:
    8696779
  • 财政年份:
    2011
  • 资助金额:
    $ 20.45万
  • 项目类别:
Functional impact of dendritic cell phenotype in a mouse model of myositis
树突状细胞表型对肌炎小鼠模型的功能影响
  • 批准号:
    8188933
  • 财政年份:
    2009
  • 资助金额:
    $ 20.45万
  • 项目类别:
Functional impact of dendritic cell phenotype in a mouse model of myositis
树突状细胞表型对肌炎小鼠模型的功能影响
  • 批准号:
    7799180
  • 财政年份:
    2009
  • 资助金额:
    $ 20.45万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 20.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 20.45万
  • 项目类别:
    Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 20.45万
  • 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 20.45万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 20.45万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 20.45万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 20.45万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 20.45万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 20.45万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 20.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了